ExploreGrowth-hormone axis
Ipamorelin
Investigational peptide
Also known as NNC 26-0161.
What's the big deal?
Ipamorelin is a synthetic peptide that stimulates your body to release growth hormone.
It's attracted attention in fitness, recovery, and longevity communities because growth hormone plays a role in tissue maintenance, metabolism, and body composition.
And there's real science behind its basic mechanism: human studies have demonstrated that ipamorelin can temporarily increase growth-hormone levels.
The catch? Increasing a hormone doesn't automatically mean building more muscle, losing fat, sleeping better, or aging more slowly.
Those benefits haven't been convincingly demonstrated in human clinical trials.
Ipamorelin is not FDA-approved.
At a glance
| Human evidence | Demonstrated GH release; limited clinical benefit evidence |
|---|---|
| FDA status | Not approved |
| Main research areas | Growth hormone, metabolism, gastrointestinal function |
| Biggest question | Does stimulating GH translate into meaningful health benefits? |
How It Works
The biology, explained.
Your body naturally releases growth hormone throughout the day, often in bursts.
This hormone helps regulate growth, metabolism, and tissue maintenance.
Ipamorelin encourages your body to release more of it.
It mimics a hunger-related hormone
Your body produces a hormone called ghrelin, which helps regulate appetite and communicates with several organs.
Ipamorelin activates the ghrelin receptor, also called the growth hormone secretagogue receptor.
This signals the pituitary gland to release growth hormone.
How is it different from tesamorelin?
Both compounds stimulate growth-hormone release, but they use different signals.
Tesamorelin mimics growth hormone-releasing hormone, or GHRH.
Ipamorelin activates the ghrelin receptor.
Think of them as two different ways to signal the same gland.
That's also why ipamorelin is frequently discussed alongside CJC-1295 and other GHRH-related compounds.
But combining them hasn't been proven to deliver better clinical outcomes.
Why was ipamorelin considered selective?
Early animal research found that ipamorelin stimulated growth hormone without producing the same significant cortisol and ACTH responses observed with certain other growth-hormone-releasing peptides.
That made it interesting to researchers.
However, those findings don't establish that ipamorelin has no effects on other hormones or is safer in humans.
Go deeper: The science
Ipamorelin is an agonist of the growth hormone secretagogue receptor, GHSR1a.
Receptor activation promotes growth-hormone release from the pituitary gland.
Its mechanism differs from GHRH analogs, which act through the GHRH receptor.
In a small human pharmacology study, growth-hormone concentrations rose after intravenous ipamorelin and subsequently declined.
The Evidence
What do the studies actually show?
Ipamorelin has been studied in humans, but its evidence is much more limited than that of FDA-approved growth-hormone therapies.
Does it actually increase growth hormone?
Yes. That part has been demonstrated.
In a 1999 human study, researchers investigated ipamorelin in healthy male volunteers.
Growth-hormone concentrations rose following administration, with a peak occurring approximately 40 minutes after infusion began.
The response was temporary.
That shows the peptide has measurable biological activity.
But it doesn't prove long-term health benefits.
What about recovery, fat loss, and muscle growth?
This is where the evidence becomes much less convincing.
There aren't adequate controlled human trials demonstrating that ipamorelin meaningfully:
- Increases muscle mass
- Reduces body fat
- Accelerates injury recovery
- Improves sleep quality
- Extends lifespan
These are popular reasons people discuss the compound, not established clinical outcomes.
An unexpected research direction: Digestion
Researchers also investigated ipamorelin for postoperative ileus, a condition in which the intestines are temporarily slow to resume normal movement after surgery.
In a randomized trial published in 2014, 117 patients were enrolled following bowel surgery.
The median time until patients tolerated a solid meal was:
| Group | Median time |
|---|---|
| Ipamorelin | 25.3 hours |
| Placebo | 32.6 hours |
That looks encouraging at first.
But the difference wasn't statistically significant.
The study did not demonstrate a reliable benefit on its main or secondary efficacy outcomes.
Why is that interesting?
It's a great example of the difference between biological activity and successful treatment.
We know ipamorelin can stimulate growth hormone.
Researchers also investigated effects on gastrointestinal movement.
But demonstrating those actions doesn't automatically mean the compound improves recovery, athletic performance, or health.
The takeaway: Ipamorelin's growth-hormone-releasing activity is established. Its popular wellness and bodybuilding benefits remain unproven.
Risks & Effects
What should people know?
Ipamorelin doesn't have an FDA-approved prescribing label, and the safety information available for many popular uses is limited.
Important concerns
Immune reactions
The FDA has identified potential risks involving immune responses, peptide aggregation, and manufacturing-related impurities.
Blood sugar and hormonal effects
Growth-hormone signaling can influence glucose metabolism and IGF-1. Whether particular risks occur with longer-term ipamorelin exposure hasn't been adequately established.
Reported adverse events in clinical research
The postoperative ileus trial included events such as nausea, vomiting, and blood-glucose abnormalities, along with serious adverse events.
FDA reviewers also discussed deaths reported during that clinical research. These reports do not, by themselves, establish that ipamorelin caused the deaths.
Unknown longer-term safety
Short studies cannot tell us what months or years of use might mean for metabolic, hormonal, or cardiovascular health.
What about injections?
Products marketed as research ipamorelin may have uncertain purity, concentration, or sterility.
An online research product isn't equivalent to a regulated, FDA-approved medication.
The FDA has also stated that it lacks sufficient safety information about certain injectable administration routes.
Bottom line: Ipamorelin's ability to raise growth hormone is real. Its overall safety for popular wellness uses is not established.
Real Experiences
What are people saying?
Ipamorelin is frequently discussed in bodybuilding, recovery, and peptide communities—often in combination with CJC-1295.
Experiences vary considerably.
The good
Some people describe deeper sleep, vivid dreams, or feeling more refreshed in the morning.
Others report better exercise recovery or subtle improvements in how they feel after training.
The not-so-good
Some people describe flushing, temporary changes in heart rate, disrupted sleep, or unusual sensations after using products labeled ipamorelin.
There are also public accounts of hives and severe allergic-type reactions.
Those symptoms deserve particular attention, even though forum posts cannot establish the specific cause.
The frustrating
Not everyone notices a benefit.
Some people report no meaningful changes in muscle growth, body composition, or recovery despite continued use.
The complicated
Many online experiences involve ipamorelin combined with CJC-1295, other peptides, supplements, or training changes.
That makes it difficult to know whether ipamorelin itself caused any reported benefit or unwanted effect.
So what should we believe?
Human research confirms that ipamorelin can stimulate growth-hormone release.
But online reports of better sleep, recovery, and body composition are not reliable evidence that it produces those benefits.
A hormone response is something we can measure. Feeling better is a much bigger scientific question.
These summaries reflect real public discussions. They are unverified personal experiences, not clinical proof or reliable estimates of side-effect frequency.
The Rest of the Notebook
For the extra-curious.
Molecular identity
| Property | Information |
|---|---|
| Type | Synthetic pentapeptide |
| Amino-acid residues | 5 |
| Sequence | Aib–His–D-2-Nal–D-Phe–Lys–NH₂ |
| Molecular formula | C₃₈H₄₉N₉O₅ |
| Molecular weight | Approximately 711.9 g/mol |
| CAS number | 170851-70-4 |
| PubChem ID | 9831659 |
| Main receptor | GHSR1a |
| Human IV elimination half-life | Approximately 2 hours |
| FDA status | Not approved |
The formula and molecular weight describe the reference free-base compound. Salt forms and formulations may have different specifications.
Storage & stability
Validated storage conditions depend on the actual formulation and supporting stability evidence.
Research-catalog recommendations do not automatically establish chemical stability, sterility, or acceptable storage periods.
There is no universal bacteriostatic-water rule applicable to every product marketed as ipamorelin.
What we still don't know
- Does ipamorelin meaningfully improve exercise recovery?
- Can it increase muscle mass in controlled human trials?
- Does it improve sleep independently of other interventions?
- What are its longer-term effects on glucose regulation and IGF-1?
- What are the risks of repeated exposure?
- Can its effects translate into clinically useful treatments?
- How do its outcomes compare with GHRH analogs?
Key research
Original pharmacology research (1998)
Raun and colleagues. Ipamorelin, the first selective growth hormone secretagogue.
Human growth-hormone research (1999)
Postoperative ileus clinical trial (2014)
FDA safety assessment
Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.
Molecular identity
Research checked: November 7, 2026.
Terms, in plain English
AgonistOpenClose
A molecule that turns a receptor on. Blocking it would be an antagonist.
Half-lifeOpenClose
How long it takes for the amount in circulation to fall by half. It is not a dosing schedule, and this library does not invent one when a study hasn’t measured it.
PharmacokineticsOpenClose
What the body does to the molecule: absorption, spread, breakdown, and clearance.